Top Story

Boo! PQRS, Value Modifier penalties for 2017 sure to scare you

October 25, 2016

From international law firm Arnold & Porter LLP comes a timely column that provides views on current regulatory and legislative topics that weigh on the minds of today’s physicians and health care executives.

On Sept. 26, CMS posted 2017 payment adjustment notices for the Physician Quality Reporting System (PQRS) and Value-Based Payment Modifier (Value Modifier) programs on the CMS Enterprise Portal. For some providers, downward payment adjustments under both programs may be as high as –6% of all Medicare services paid under the Physician Fee Schedule (PFS) in 2017 (–2% for PQRS and –4% for Value Modifier). Providers have until Nov. 30 to submit informal review requests to CMS if they believe they have been incorrectly assessed a negative payment adjustment under either program.

Cover Story

Facts, not fear, should guide decisions about contralateral prophylactic mastectomy

HemOnc Today, October 25, 2016
The percentage of women with invasive breast cancer who undergo contralateral prophylactic mastectomy has skyrocketed, even though evidence suggests the procedure…

Should women be required to meet specific risk criteria to undergo contralateral prophylactic mastectomy?

HemOnc Today, October 25, 2016
POINT Rates of contralateral prophylactic mastectomy (CPM) among women in the United States with unilateral breast cancer have been increasing, and this trend shows no signs…

Animal Farm, 1984 and The Hunger Games

HemOnc Today, October 25, 2016
Derek Raghavan, MD, PhD
There was a time when Animal Farm and 1984 seemed to be apocryphal, even fanciful representations of political despotism and manipulation. Of course, time showed that…
In the JournalsPerspective

Training, collaboration key to overcoming ‘inadequacies of care’ for sickle cell disease

HemOnc Today, October 25, 2016
Outcomes for individuals with sickle cell disease have improved markedly in recent decades. More than 90% of children in the developed world born with the inherited…
More News Headlines »

The Patient with Multiple Ecchymoses

No commercial support for this activity.

Glanzmann’s thrombasthenia is a rare, inherited bleeding disorder that results from a mutation in αIIbß3, an integrin…
More »
Meeting News Coverage

VIDEO: Long-term nivolumab therapy produces ‘exciting’ results in kidney cancer

September 9, 2016
More »

Immunotherapy Updates 2015: FOCUS on NSCLC

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty-five percent of lung cancers are non-small…
More »
Current Issues
View the Current Issue
HemOnc Today